#PROpelStudy Archives

ASCO-GU Interview | Dr. Xuefeng Qiu: Timely Testing and Treatment, Let mCRPC patients benefit more from PARPi precision treatment

By Mourabit Halima 2024.03.06

Editor's Note: The annual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) was held in San Francisco, USA, from January 25 to 27, 2024. The conference presented updates…

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: Following the breakthrough of the PROfound study, which marked the beginning of precision treatment for prostate cancer, the PROpel study has further extended the application of PARP inhibitors…

ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC

By Mourabit Halima 2024.03.04

Editor's note: At the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) held recently, data on patients with homologous recombination repair mutations (HRRm) from the PROpel study…

ASCO-GU Interview | Dr. Junlong Zhuang Interprets the BRCAAway Study and Real-World Genetic Testing in Advanced Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: In the field of metastatic castration-resistant prostate cancer (mCRPC), the PROfound study marked the beginning of the era of precision targeted therapy for prostate cancer, while the PROpel…